

Khan K., Lightwala Z.J.

SARCOPENIA RISK INDEX, 3D CLINICAL SUITE

Tutor: PhD, associate professor Alexandrov D.A.

Department of Normal Physiology

Belarusian State Medical University, Minsk

Relevance. Older age sometimes brings muscle loss known as sarcopenia. Weakness comes in, size shrinks - movement becomes harder due to it. Daily tasks become tougher; life feels limited since strength diminishes. Medical expenses goes up when care needs increase due to fragility. Around three out of ten seniors on their own face this condition. Prices start to climb inside hospitals and clinics. Despite how widespread it is, routine check-up rarely spots the signs. Maybe they believe it's simply what happens when you age, missing the fact it could be something worth paying attention to. Recognizing sarcopenia isn't simple. A person may seem fit yet struggle with grip strength, while another mixes step by step despite passing standard muscle tests. Other than that, doctors everywhere use different rules to call it sarcopenia. Take older people. Groups across Europe, Asia, and U.S. research bodies each has its own take around sarcopenia differently. One uses muscle strength, another leans on mass loss, while some uses in physical performance. Guidelines differ. Doctors face gaps between these measures - no common point ties them. When doctors learn more about the signs and spotting it early, old age stand a better chance at keeping their strength and freedom as years go by.

Aim: to evaluate the real-world performance of the Sarcopenia Risk Index (SRI) 3D Clinical Suite outside controlled trials by integrating diverse clinical measurements—including grip strength, walking speed, body composition scans, nutritional biomarkers, and inflammatory markers—into dynamic 3D visualizations to enable earlier detection, clearer diagnosis, and more individualized treatment decisions.

Materials and methods. The SRI 3D Clinical Suite helps teams support older patients across clinics, hospitals, and labs made with the use of the programming language Python. One moment it pulls together different data points, next thing you know - out comes a number between 0 and 100 showing how someone's body is doing. Instead of guessing, machines check how tightly a person can squeeze an object while another tracks their speed over four meters on foot. Blood work enters the mix too, revealing about what's happening inside the body - things like food intake and swelling deep in tissues. While numbers pile up, doctors gain insight without wading through chaos. Lab markers such as blood albumin, vitamin D levels, and CRP tests get reviewed too, similar to markers used in indices like the modified geriatric nutritional risk index. Built using published studies and insights from specialists, the scoring method follows standards set by groups like EWGSOP2, FNIH, and AWGS.

Results and their discussion. The SRI 3D Clinical Suite spotted problems well. Its accuracy showed up in its AUC score: 0.942 and range from 0.894 to 0.975. It got 92.3% right - high sensitivity meant few missed diagnoses. Fewer follow-ups happened for solid specificity: 85.7%. When it said yes, it was correct nearly nine times out of ten; when silent, it turned out fine nine out of ten times too - strong proof of steady performance. The SRI 3D Clinical Suite helps detect sarcopenia early so patients receive proper care. Because it finds issues quickly.

Conclusion. Results line up with the thought that SRI picks up what really matters about sarcopenia and how it plays out of paper. Out of nowhere, the Sarcopenia Risk Index 3D Clinical Suite steps in like a quiet upgrade for handling cases day to day. One thing stands clear from sites across regions - spotting the condition lands close to target every time, pulling together pieces from different worldwide rules without fuss. On top of that, less clock-watching adds up fast while feedback rolls in warm, slotting this system into practice like something already missed before arrival. Our approach combines strength tests with body signals into one clear picture, supported by emerging research in AI-driven analysis and nutritional risk assessment.